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There is an urgent and unmet need for humanized in vivo models
of type 1 diabetes to study immunopathogenesis and immuno-
therapy, and in particular antigen-specific therapy. Transfer of
patient blood lymphocytes to immunodeficient mice is associated
with xenogeneic graft-versus-host reactivity that complicates
assessment of autoimmunity. Improved models could identify
which human T cells initiate and participate in beta-cell destruction
and help define critical target islet autoantigens. We used
humanized mice (hu-mice) containing robust human immune
repertoires lacking xenogeneic graft-versus-host reactivity to
address this question. Hu-mice constructed by transplantation of
HLA-DQ8+ human fetal thymus and CD34+ cells into HLA-DQ8–
transgenic immunodeficient mice developed hyperglycemia and
diabetes after transfer of autologous HLA-DQ8/insulin-B:9–23
(InsB:9–23)-specific T-cell receptor (TCR)-expressing human CD4+
T cells and immunization with InsB:9–23. Survival of the infused
human T cells depended on the preexisting autologous human
immune system, and pancreatic infiltration by human CD3+
T cells and insulitis were observed in the diabetic hu-mice, pro-
vided their islets were stressed by streptozotocin. This study fits
Koch’s postulate for pathogenicity, demonstrating a pathogenic
role of islet autoreactive CD4+ T-cell responses in type 1 diabetes
induction in humans, underscores the role of the target beta-cells
in their immunological fate, and demonstrates the capacity to ini-
tiate disease with T cells, recognizing the InsB:9–23 epitope in the
presence of islet inflammation. This preclinical model has the po-
tential to be used in studies of the pathogenesis of type 1 diabetes
and for testing of clinically relevant therapeutic interventions.
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Type 1 diabetes mellitus (T1D) is an autoimmune diseaseresulting from immune destruction of insulin-producing
β cells in the pancreatic islets. Autoreactive T cells recognizing
β-cell antigens (e.g., insulin) are believed to play a critical role in
disease onset and progression, but direct evidence for this is still
lacking (1). The loss of β cells and the subsequent reduction or
lack of insulin result in chronic elevation of blood glucose levels,
leading to severe complications such as heart disease, stroke, and
kidney failure. Patients with T1D rely on exogenous insulin to
control the disease (2), but insulin therapy does not eliminate the
risk for T1D complications and may be associated with life-
threatening hypoglycemia (3). Thus, new therapies are urgently
needed for T1D treatment. Recent insight into the human dis-
ease lesion in the pancreas indicated profound differences in
immunopathology between patients with T1D and the nonobese
diabetic mouse model that is regarded as the nearest preclinical
model of autoimmune diabetes (4). These observations, com-
bined with a range of other differences in the immune systems of
humans versus mice, prompted us to design preclinical models in
which the immune system is humanized to study both disease
mechanisms and immunotherapeutic strategies (5).
In this study, we sought to overcome this issue, using humanized
mice (hu-mice), by infusing autologous hu-mouse–derived human
T cells engineered with a TCR that recognizes the HLA-DQ8–
restricted insulin B chain peptide consisting of amino acids 9–23
(InsB:9–23). InsB:9–23 is a dominant MHC class II-restricted antigen
recognized by islet-infiltrating insulin-specific T cells and serves as an
essential target of the immune destruction of pancreatic β cells in
nonobese diabetic (NOD) mice (6, 7). Previous observations sug-
gested this epitope may also serve as a key autoantigenic target in
humans, as it does in mice. HLA class II-restricted T-cell response to
InsB:9–23 peptide is highly associated with T1D in humans (8). A
recent study using HLA-DQ8/B:11–23R22E tetramers further con-
firmed the presence of CD4 T cells recognizing the HLA-DQ8–
restricted B:11–23 peptide in patients with T1D (9). More recently,
2.35% of CD4 T-cell clones isolated from inflamed islets of patients
with T1D were found to recognize InsB:9–23 (10). However, there
has been no direct evidence for human InsB:9–23-reactive T-cell–
mediated in vivo destruction of pancreatic β cells in humans.
Our data showed that adoptive transfer of HLA-DQ8–restricted
InsB:9–23-specific human CD4 T cells is capable of inducing di-
abetes in HLA-DQ8–Tg hu-mice, consistent with the potential of
T-cell responses to the InsB:9–23 epitope to initiate T1D in humans.
Results
The TCR α (Vα21) and β (Vβ11) chain cDNA was extracted from an
InsB:9–23-specific human T-cell line (clone #5), which was estab-
lished from blood from an 18-y-old Caucasoid HLA-DQ8 homozy-
gous man diagnosed with T1D at the age of 8 y (11, 12), and linked
by a P2A self-cleaving peptide gene. The TCRα-P2A-β gene frag-
ment was then linked to a F2A-AcGFP gene fragment, and then
cloned into a lentiviral vector (LV-insTCR; Fig. S1). To assess the
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efficacy of cell surface TCR expression of the engineered human
T cells, we measured TCR expression on the TCR-negative human
cell line J.RT3-T3.5 cells after transduction with LV-insTCR. Flow
cytometric (FCM) analysis revealed that all transduced, that is,
GFP+, J.RT3-T3.5, cells gained cell surface expression of human
CD3 (Fig. S2A) and αβTCR (Fig. S2B). All GFP+ cells were also
stained positively for human TCRvβ11, further confirming the ex-
pression of the engineered B:9–23-specific TCR on the transduced
cells (Fig. S2C). Together, these results confirmed that efficient
cell surface expression of the diabetogenic TCR in human T cells
can be achieved via lentiviral transduction.
InsB:9–23 is a dominant epitope recognized by autoreactive
T cells in both patients with T1D and NOD diabetic mice (8, 13).
Because the TCR used in this study recognizes an HLA-DQ8–
rectricted InsB:9–23 peptide, we used HLA-DQ8+ human fetal
thymus (FTHY) and CD34+ cells isolated from fetal liver cells
(FLCs) to construct hu-mice and used HLA-DQ8–Tg hu-mice as
the recipients of the engineered human T cells (Fig. 1A). Adoptive
transfer of peripheral blood mononuclear cells (PBMCs) from
patients with T1D (14, 15) or human T cells that were virally
transduced to express β-cell-specific TCRs (16) into immunodefi-
cient mice has been explored previously to characterize the β-cell-
specific autoimmune responses of human T cells, and the results
demonstrated the potential of these models to facilitate un-
derstanding of the immunopathogenesis of human T1D. However,
although survival and islet infiltration of the transferred human
T cells were clearly detected in the recipient mice carrying the
diabetogenic HLA transgene matched to the diabetic patient do-
nors, none of the recipient mice developed diabetes. The presence
of human T cells reactive to xenogeneic mouse antigens and
varying degrees of graft-versus-host disease (GVHD) were con-
founding factors in the evaluation of antigen-specific immune re-
sponses in these studies (14–16). Indeed, previous studies have
shown that xeno-GVH responses can result in global T-cell anergy
of transfused human T cells even when they do not cause overt
GVHD (17). To avoid both anti-human allogenic and anti-
recipient mouse xenogeneic immune responses, self- and mouse-
tolerant human T cells (18) from autologous hu-mice were used to
generate InsB:9–23-specific T cells, which were then adoptively
transferred into HLA-DQ8–Tg hu-mice with an autologous im-
mune system (i.e., hu-mice used as the recipients and those used
as the source of InsB:9–23-specific T cells were made by FTHY
and CD34+ FLCs from the same fetus; Fig. 1A). Human lym-
phohematopoietic cell reconstitution in hu-mice was monitored by
FCM analysis of peripheral blood human cells. Fig. 1B shows
the kinetics of human CD45+, CD19+ B, CD3+, and CD3+CD4+
T cells in PBMCs from a representative experiment, in which the
level of human CD3+ T cells in all hu-mice examined was greater
than 30% in PBMCs by 15 wk after humanization.
To collect human CD4+ T cells for genetic engineering, spleens
were harvested from hu-mice between 15 and 17 wk after human-
ization. After confirming high levels of human T-cell reconstitution
by FCM analysis of PBMCs and spleen cells (Fig. 2A), human CD4+-
naive T cells were enriched by depletion of mouse cells and human
CD14+, CD19+, CD8+, CD45RO+, and CD25+ cells. The purified
cell population consisted of ≈85% human CD3+CD4+ T cells, with
the majority of the cells expressing a CD45RA+CD45RO−CD25−
naive phenotype (Fig. 2B). The human naive CD4+ T-cell–enriched
cells were preactivated by anti-human CD3/CD28 Dynabeads, fol-
lowed by incubation with LV-insTCR. The transduced human T cells
were then expanded for 10–14 d with irradiated feeder cells plus
human cytokines (IL-2, IL-7, and IL-15) and PHA (phytohemag-
glutinin) or OKT3 (ortho Kung T-cell 3). Using this protocol, we
were able to achieve ≈130–200-fold expansion in numbers (Fig.
S3). At the end of culture, the majority of the expanded cells were
CD3+CD4+ T cells with more than 80% of the cells expressing the
engineered TCR, as identified by coexpression of GFP and TCRvβ11
(Fig. 2C). The expanded human CD4+ T cells were used immedi-
ately in an effort to induce diabetes in HLA-DQ8–Tg hu-mice.
We initially injected the InsB:9–23-TCR-engineered human
CD4+ T cells into HLA-DQ8–Tg NSG mice or hu-mice that
were grafted 14 wk earlier with autologous human CD34+ FLCs
(without FTHY; these hu-mice contained human antigen-
presenting cells, but not T cells). FCM analysis revealed that
the infused human GFP+CD4+ T cells were detectable for at
least 17 d in the spleen and 42 d in bone marrow from hu-mice
grafted with human CD34+ FLCs, but not in these tissues from
control NSG mice (Fig. S4A). The lack of detectable GFP+CD4+
T cells in NSG mice is consistent with our previous studies
showing that the engrafted human CD34+ FLC-derived cells,
likely antigen-presenting cells, play an important role in the
survival and/or expansion of infused human T cells when there is
no xeno-GVH reactivity (19). However, neither HLA-DQ8–Tg
hu-mice nor NSG mice developed diabetes or hyperglycemia
after infusion of InsB:9–23-TCR-engineered human CD4+
T cells (Fig. S4B). Injection of InsB:9–23-TCR-engineered hu-
man CD4+ T cells also failed to induce diabetes or hyperglyce-
mia in low-dose streptozotocin-treated HLA-DQ8–Tg hu-mice
that were grafted 14 wk earlier with autologous human CD34+
FLCs and FTHY (Fig. S4C).
Considering the fact that the TCR used in this study was


















Fig. 1. Preparation of hu-mice for generating InsB:9–23-specific T cells and for induction of diabetes. (A) Schematic showing preparation of both donor hu-
mice with HLA-DQ8+ human immune reconstitution, from which splenic human CD4+-naive T cells are prepared, transduced with LV-insTCR, expanded, and
injected into recipient hu-mice for diabetes induction, and recipient HLA-DQ8–Tg hu-mice reconstituted with human immune cells autologous to the donor
hu-mice, which are used as the recipients of LV-insTCR–transduced CD4+ T cells. (B). Levels (mean ± SEM) of human hematologic and immune cell chimerism in
PBMCs of hu-mice from a representative experiment.



















to endogenously processed peptides (10), in the subsequent ex-
periments, we immunized the HLA-DQ8–Tg hu-mice (grafted
14 wk earlier with human CD34+ FLCs and FTHY) with InsB:9–23
peptides in CFA adjuvant 1 d after injection of InsB:9–23-TCR-
engineered or control human CD4+ T cells. FCM analysis con-
firmed the presence of the infused LV-insTCR–transduced (i.e.,
GFP+) human CD4 T cells in blood and tissues, including pancreas
from the recipient hu-mice (Fig. 3). The infused LV-insTCR–
transduced (i.e., GFP+) CD4+ T cells were detectable for days in
peripheral blood (Fig. 3A), and for at least 3 wk in the spleen and
liver and 5 wk in bone marrow (Fig. 3B) in the diabetic hu-mice.
Moreover, human CD45+ cells, including CD11c+HLA-DR+ DCs,
CD19+ B cells, and CD3+ T cells (nearly 50%, including both GFP+
and GFP− T cells) were detected in the islets 11 d after infusion of
LV-insTCR–transduced (GFP+) human CD4 T cells (Fig. 3C).
GFP+ T cells were also detected by histology in the pancreatic islets
from the hu-mice 3–4 wk postinfusion of LV-insTCR–transduced
T cells (Fig. 3D). Importantly, ≈60% of the hu-mice receiving
InsB:9–23-TCR-engineered human T cells developed hyperglyce-
mia and diabetes, whereas none of the similarly conditioned hu-
mice receiving control human T cells and InsB:9–23 immunization
had hyperglycemia (Fig. 4A). Histological analysis demonstrated
severe destruction of mouse pancreatic islets and associated human
CD3+ T-cell infiltration in the diabetic, but not the control, hu-mice
(Fig. 4 B and C). Collectively, these data indicate that human
T cells engineered with InsB:9–23-TCR are functional and ca-
pable of inducing insulitis and diabetes after adoptive transfer into
HLA-DQ8–Tg hu-mice.
Discussion
Animal models have been crucial in understanding the patho-
genesis and testing of therapeutic interventions for T1D. How-
ever, because of differences between animals and humans,
information learned from animal models often does not apply to
humans, and most therapeutic approaches effective in animals
are not successful in the clinic (20). For these reasons, hu-mouse
models have been increasingly used in the study of human dis-
eases and therapies. Efforts have been made to model T1D by
transferring peripheral blood of patients with T1D to immuno-
deficient mice with the diabetes-prone NOD background. Al-
though some of these approaches have indeed led to insulitis (14,
21, 22), the models are limited by the restriction to blood, where
the most relevant T cells may not reside (23), as the source of
human T cells. An additional limitation is the propensity of
human T cells to cause xenogeneic GVHD when transferred to
immunodeficient mice (24, 25). Although GVHD may be pre-
vented by using autoantigen-expanded T-cell lines or clones (21),
this approach has not allowed assessment of the role of re-
cruitment of other human T cells and immune cells in disease
pathogenesis. Our study describes a hu-mouse model of T1D in
mice with established robust immune systems and which lack
GVHD. Direct study of human T1D pathogenesis is thereby
afforded through insulin-reactive human T-cell–mediated dis-
ease induction in the presence of an autologous human lym-
phohematopoietic system. Despite its complexity and the other
limitations of the rodent host, this model may prove useful for
testing clinically relevant therapeutic interventions.
Autoreactive T cells recognizing β-cell antigens (e.g., insulin)
are believed to play a critical role in disease onset and progres-
sion, but the primary antigens eliciting disease in humans remain
unknown, and this question cannot be investigated. Using hu-
mice, this study provides definitive proof that human islet
autoreactive T cells carrying a TCR isolated from a patient with
T1D can be diabetogenic in vivo, and demonstrates a possible
pathogenic role of CD4+ T-cell responses to the InsB:9–23 epi-
tope in T1D induction in humans. The TCR used in this study
was isolated from a blood-derived T-cell clone, which, unlike
islet-derived T-cell clones, does not recognize islets directly (10).
According to Unanue’s classification, this is a type B clone that
escapes from negative selection in the thymus and gets activated
in periphery (26). These observations suggest that in our model,
the peptide immunization may play an important role in acti-
vating the transferred InsB:9–23-reactive human CD4 T cells.
Our observation that streptozotocin treatment precipitated
T-cell–mediated beta-cell destruction is in line with the popular
notion that beta cells are involved in their own demise through
their dialogue with the immune system (27). Indeed, recent data
point out that beta-cell stress increases their vulnerability, im-
munogenicity, and attraction by the immune system (28). The
beta-cell stress induced by perturbation with streptozotocin in
our hu-mice model would act as an important checkpoint in the
induction of beta-cell destruction mediated by islet autoreactive
T-cells after loss of immune tolerance.
An important difference from previous studies (14–16) is that
in the present study, diabetogenic human T cells were injected
into hu-mice with an established human immune system. These
hu-mice have high levels of human lymphohematopoietic cell
reconstitution and formation of secondary lymphoid organs (e.g.,
white pulp in the spleen and follicular structure in lymph nodes),
Fig. 2. Purification and lentiviral transduction of hu-mouse–derived human
CD3+CD4+CD45RO−CD25−-naive T cells. Spleen cells were prepared from
donor hu-mice between 15 and 17 wk after humanization, as indicated in
Fig. 1A, and human CD4+-naive T cells were prepared by MACS negative
selection, using antibodies against mouse cells (anti-mCD45 and Ter119) and
human cells expressing CD8, CD14, CD19, CD25, or CD45RO and transduced
with LV-insTCR. (A) FCM profiles of human CD45+, CD3+, CD19+, CD3+CD4+,
and CD4+CD8+ cells in the pooled spleen cells from donor hu-mice. (B) Purity
of the MACS-selected hu-mouse spleen cells. Shown are the percentage of
human CD3+CD4+ T cells and their expression of CD45RO, CD45RA, and
CD25. (C) Expression of human CD3, CD4, and TCRvβ11 on the in vitro ex-
panded LV-insTCR–transduced GFP+ cells.
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and are capable of mounting in vivo antigen-specific immune
responses after antigen immunization or transplantation (29–31).
The human immune cells from recipient hu-mice might also be
involved in the immune destruction of pancreatic β cells. They
were clearly essential for the prolonged survival of infused
autoreactive T cells in our study (Figs. S4A and S5), consistent
with the role that human antigen-presenting cells were shown to
play in facilitating the survival, expansion, and phenotypic con-
version of human T cells in hu-mice when xeno-GVH reactivity is
absent (19). In addition, the presence of both GFP+ and GFP−
human CD3+ T cells in the pancreatic islets from hu-mice re-
ceiving LV-insTCR–transduced (i.e., GFP+) human CD4 T cells
(Fig. 3) suggests a possible contribution of recipient endogenous
human T cells to the disease development. T cells recognizing
numerous antigenic epitopes, including others of insulin, gluta-
mate decarboxylase, islet specific glucose 6 phosphatase catalytic
subunit related protein, and the islet tyrosine phosphatase IA-2,
are associated with T1D in humans and NOD mice (32). Al-
though T cells specific for InsB:9–23 may be required for ignition
of T1D, the development and progression of the disease might
also involve functional epitope spreading (7, 33). Further studies
are needed to precisely understand the role of the recipient
human immune cells in the development of diabetes in hu-mice
infused with human diabetogenic T cells.
Our hu-mice model will allow investigation of the pathogenicity
and recruitment of human islet autoreactive T-cells, as well as
identify their potentially initiating or pathogenic target beta-cell
autoantigens, rendering this model uniquely suited to investigate
antigen-specific immunotherapy in T1D in preclinical models
in vivo that hitherto was impossible with any other animal model.
Materials and Methods
Animals and Human Tissues and Cells. The NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ
(NSG) mice and NOD.Cg-Prkdcscid H2-Ab1tm1Doi Tg(HLA-DQA1,HLA-DQB1)
1Dv/SzJ (HLA-DQ8–transgenic NOD/SCID) mice were purchased from the
Jackson Laboratory. HLA-DQ8–transgenic NSG mice were generated by
crossing HLA-DQ8–Tg NOD/SCID mice with NSG mice. All mice were housed
in a specific pathogen-free microisolator environment and used between
6 and 12 wk of age. Human FTHY and liver tissues of gestational age of
17–21 wk were obtained from Advanced Bioscience Resource. J.RT3-T3.5 cell
line, a TCRβ chain-deficient human T-cell line derived from the E6-1 clone of
Jurkat cells that does not express CD3 or TCRαβ heterodimers on the surface
(34), was purchased from American Type Culture Collection (ATCC TIB-153).
Protocols involving the use of discarded human tissues and animals were
approved by the Columbia University Medical Center Institutional Review
Board and the Institutional Animal Care and Use Committee, respectively,
and all experiments were performed in accordance with these protocols.
Humanized Mouse Preparation. Hu-mice were constructed as described in our
previous studies (29, 35). Briefly, NSG and HLA-DQ8–Tg NOD/SCID or NSG
mice were conditioned with sublethal (1.5 Gy) total body irradiation and
received human CD34+ FLCs (1 × 105, i.v.) and a FTHY tissue fragment
(≈1 mm3; under the kidney capsule) from the same fetus.
HLA-DQ8/InsB:9–23-Specific TCR Isolation and Lentiviral Vector Construction.
After informed consent, peripheral blood was drawn from an 18-y-old
Caucasoid HLA-DQ8/8 homozygous man diagnosed with T1D at the age of
8 y, and a T-cell line (clone #5) was generated by stimulation with InsB6-22
(the epitope being identical in B:9–23, and the T cells cross-react with B:9–23)
(11, 12). The TCR α and β chain cDNA were extracted and linked by a P2A
self-cleaving peptide gene (36). The TCR α-P2A-β gene fragment was then
linked with a F2A-AcGFP (aequorea coerulescens green fluorescent protein)
gene fragment and then cloned into a lentiviral vector (LV-insTCR; Fig. S1).


































Fig. 3. Survival of the infused LV-insTCR–transduced human CD4+ T cells in hu-mice. (A) Survival of GFP+CD4+ T cells in peripheral blood from hu-mice at
3 and 6 d after cell transfer. Data from two hu-mice at each point are shown. (B) Presence of GFP+CD4+ human T cells in spleen, liver, and bone marrow cells of
two representative hu-mice analyzed at 3 and 5 wk, respectively, after cell transfer. (C) Pancreatic islets were prepared from hu-mice 11 d after infusion of LV-
insTCR–transduced human CD4+ T cells, digested with trypsin, and stained with the indicated antibodies to detect human cell infiltration by flow cytometry.
(D) Pancreatic tissue sections were prepared from hu-mice between 3 and 4 wk after injection of LV-InsTCR–transduced GFP+ human T cells (n = 3), and stained
with anti-GFP antibodies. Shown are representative immunohistochemistry images of pancreas sections from hu-mice receiving LV-InsTCR–transduced GFP+
(Top) or control (Bottom) human T cells.



















2000 (Invitrogen) of 293T cells with a four-plasmid system consisting of the trans-
fer vector (LV-insTCR) and three packaging plasmids (pMD2.G, pMDLg/pRRE,
and pRSV-Rev). The supernatant with viral particles was collected 48 and 72 h
posttransfection and concentrated by ultracentrifugation at 50,000 × g for 2 h.
Lentiviruses were stored at −80 °C until use.
Flow Cytometric Analysis. Levels of human hematopoietic cells in humanized
mice were determined by FCM analysis of PBMCs and splenic cells, using
various combinations of the following monoclonal antibodies: anti-human
CD45, CD19, CD3, CD4, CD8, CD45RA, CD45RO; anti-mouse CD45 and
Ter119; and corresponding isotype controls (all purchased from Biolegend).
Human T cells transduced with B:9–23-specific TCR (using Vα21 and Vβ11) were
identified by staining with anti-human TCRvβ11-FITC (mouse IgG2a; Beckman
Coulter) followed by anti-mouse IgG2a-PE secondary mAb (Biolegend).
The secondary anti-mouse IgG2a-PE was required to distinguish between
GFP-positive cells with and without TCRVβ11 expression, as all virally trans-
duced cells are expected to express AcGFP (Fig. S1). To detect human im-
mune cell infiltration in pancreatic islets, islets were prepared and
dissociated with trypsin and stained with anti-human CD45, CD3, CD19,
CD11c, HLA-DR, and anti-mouse CD45. Samples were collected on a FACS LSR
II (Becton Dickinson) and analyzed with FlowJo software (TreeStar). Dead
cells were excluded from the analysis by gating out DAPI-positive cells.
Lentiviral Transduction of Human CD4+ T Cells from Humanized Mice. Hu-mouse
spleen cells enriched for human CD4+-naive T cells were prepared by nega-
tive separation using magnetic-activated cell sorting (MACS; Miltenyi Biotec).
Briefly, spleen cells were stained with PE-conjugated mAbs against mouse
Ter119, mouse CD45, huCD14, huCD19, huCD8, huCD45RO, and huCD25, fol-
lowed by incubation with anti-PE magnetic beads (Miltenyi) and MACS column
purification. The purified human CD4+-naive T cells were stimulated for 3.5 d in
medium containing human T-Activator CD3/CD28 Dynabeads (Gibco Life
Technologies), followed by incubation with lentiviruses in 96-well plates pre-
coated with retronectin (Takara Bio Inc) for 24 h at a multiplicity of infection of
40. Cells were washed twice and expanded for 10–14 d in vitro in T-cell ex-
pansion medium (RPMI 1640 supplemented with 10% human AB serum),
irradiated feeder cells, recombinant human cytokines (20 U/mL IL-2, 10 ng/mL
IL-7, and 10 ng/mL IL-15; R&D), plus PHA (1.5 μg/mL, Cat# L1668-5 mg; Sigma)
or anti-CD3 mAb (OKT3; 30 ng/mL, Cat# NC9195482; Thermo Fisher). Feeder
cells were 35-Gy-irradiated pooled allogeneic PBMCs (3 × 106/mL) and 60-
Gy-irradiated Epstein-Barr virus-transformed lymphoblastoid cell lines
(1.5 × 105/mL). The expanded cells were injected into hu-mice immediately
in efforts to induce diabetes.
Induction of Diabetes in HLA-DQ8–Tg Hu-Mice. The HLA-DQ8–Tg hu-mice on
the NOD/SCID or NSG background were conditioned with two successive low
doses of streptozotocin (50 mg/kg/d × 2 d, i.p.; Sigma) starting 1 or 2 d be-
fore adoptive transfer of lentivirally transduced human CD4+ T cells derived
from preestablished hu-mice with an autologous (same fetal tissue donor)
immune system (i.e., hu-mice made with the same fetal tissues as the
adoptive recipient hu-mice). In some experiments, the HLA-DQ8–Tg hu-mice
were also immunized with 100 μL (100 μg) InsB:9–23 peptide (SHLVEA-
LYLVCGERG; AnaSpec, Inc.) in 100 μL Freud’s Complete Adjuvant (InvivoGen)
by s.c. injection 1 d after human CD4+ T-cell transfer. Blood glucose levels
were monitored twice a week, using FreeStyle blood glucose test strips and a
blood glucose meter (Abbott Diabetes Care Inc.). Mice were considered di-
abetic after two consecutive blood glucose measurements >200 mg/dL (37).
Immunofluorescent Staining of Pancreatic Tissues. Pancreata were harvested
from the hu-mouse recipients between 3 and 4wk after injection of CD4+ T cells,
and fixed in 4% paraformaldehyde for histological analysis. Briefly, frozen
sections were prepared and stained with anti-insulin (guinea pig IgG; Dako),
anti-glucagon (rabbit IgG; Sigma), anti-human CD3-Alexa Fluor 488 (Biolegend),
followed by staining with donkey anti-guinea pig IgG-Cy5 (H+L; Jackson
ImmunoResearch) and donkey anti-rabbit IgG-Dylight (H+L; Jackson Immuno-
Research). All sections were mounted in Vectorshield with DAPI (Vector Labo-
ratories). Images were obtained using Leica DMI 6000B wide-field microscope.
Statistical Analyses. The log-rank (Mantel-Cox) test was used analyze the dif-
ference in the incidence of diabetes between groups. A P value of ≤0.05 was
considered significant.
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Fig. 4. Induction of diabetes in HLA-DQ8–Tg hu-mice by adoptive transfer of autologous diabetogenic human CD4+ T cells. HLA-DQ8–Tg hu-mice were treated with
low-dose streptozotocin and injected 1–2 d later with 5 × 106 expanded LV-insTCR–transduced or control (i.e., the same hu-mouse–derived human CD4+ T cells that
were similarly expanded in vitro as the LV-insTCR–transduced CD4+ T cells) human CD4+ T cells, followed 1 d later by immunization with InsB:9–23 peptides.
(A) Cumulative incidence of diabetes (Top) and levels of blood glucose (Bottom) in hu-mice receiving LV-insTCR–transduced (solid symbol; n = 7) or control (opened
symbol; n = 6) human T cells. Mice were defined as hyperglycemia if two consecutive blood glucose measurements >200 mg/dL (B and C) Immunofluorescent staining
of pancreas samples prepared between 3 and 4 wk after injection of CD4+ T cells from hu-mice receiving control (Left) or LV-InsTCR–transduced (Right) human T cells
(n = 3 per group). (B) Staining of mouse insulin (yellow) and glucagon (red). (C) Staining of human CD3+ cells (green), mouse insulin (pink) and glucagon (red). Nuclear
is stained blue by DAPI.
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